MindMed Q3 net loss $16.5M, cash $154.5M; Phase 2b GAD trial on track for H2 2023 readout

Definium Therapeutics, Inc.

2022-Q3 EPS reported -$1.82

Net loss of $16.5M for Q3 2022 vs $17.2M in Q3 2021; nine-month net loss $51.9M vs $76.2M.
Cash and equivalents $154.5M as of Sept 30, 2022; expected to fund operations into first half of 2025.
Raised ~$60M in gross proceeds via at-the-market program and public offering during Q3.
Phase 2b dose-optimization trial of MM-120 (LSD) in GAD initiated; topline data expected H2 2023.
Advanced IND-enabling studies for MM-402 (R-MDMA) for autism; Phase 1 planned for 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Definium Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $16.5 million.

Period: the quarter ended September 30, 2022
Net income: $16.5 million
Result: reported results

Exact text from the filing

The net loss for the three months ended September 30, 2022 was $16.5 million

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024182

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.